TP53 and acute myeloid leukemia: Notably, two primary AML patients with >25% BM blasts and unfavorable cytogenetics (del 5q and monosomy 7 in UPN28) and/or adverse risk group genomic mutations (TP53 mutation in UPN28 and ZRSR2 in UPN21) achieved a PR at 58 days and 75 days, respectively, which deepened to a CR with full hematologic recovery at 92 and 113 days, respectively (Figure 2).